Ozkan Alan

50PUBLICATIONS

303CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsImmunogenetics (incl. genetic immunology)Predictive and prognostic markersAutoimmunity

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (50)

Sort by Publication Date:

|Jul 15, 2026

Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study.

|Jun 25, 2026

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

|May 27, 2026

Immune Checkpoint Inhibitor-Associated Immune-Mediated Nephropathy: A Real-World Pharmacovigilance Study.

|May 27, 2026

Prognostic Impact of PET/CT-Derived Sarcopenia in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

|May 06, 2026

Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS).

|May 04, 2026

Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change.

Pageof 9

Frequent Collaborators

10 joint publications

Seda Jeral Evinç

10 joint publications

Murad Guliyev

10 joint publications

Murat Günaltılı

Tuğba Akın Telli

Hamza Abbasov

Zeliha Birsine

Perran Fulden Yumuk

Goncagul Akdag

Tugba Basoglu Tuylu

Hatice Odabas

Frequent Collaborators

10 joint publications

Seda Jeral Evinç

10 joint publications

Murad Guliyev

10 joint publications

Murat Günaltılı

9 joint publications

Tuğba Akın Telli